New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Enveric Biosciences, Inc.
ENVB
Shape
US Flag

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

3M

Biotechnology

Next Earning date - 24 Mar 2025

3M

Biotechnology

Next Earning date - 24 Mar 2025

1.73USD

Shape0.09 ( 5.49%)
Market Closed (as of Mar 14, 20:00 EDT)
favorite-chart

Relative Strenght

1
favorite-chart

Volume Buzz

-97%
favorite-chart

Earning Acce

Yes
favorite-chart

Dist 52w H.

99%
OverviewChart

Quote Panel

Shape
Updated March 24, 2025
1W 2.96 % 1M 47.46 % 3M -62.58 % 1Y -88.95 %

Key Metrics

Shape

  • Market Cap

    3.34M

  • Shares Outstanding

    1.92M

  • Share in Float

    1.81M

  • Dividende

    0

  • Earning Date

    24 Mar 2025

  • Price Target

    1.74

  • Average Volume

    2.95M

  • Beta

    0.084

  • Range

    1.13-267.75

  • Industry

    Biotechnology

  • Website

    https://www.enveric.com

  • Sector

    Healthcare

Fundamentals

Shape

Relative Strength

Shape

ENVB

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

Analyst rating

Last analyst upgrade/downgrade

Earnings GrowthShape

status-upYoY

Current

Estimates

Q4.22

arrow
arrow

N/A

-6.76
vs -90.97

Q1.23

arrow
arrow

N/A

-11.24
vs -104.95

Q2.23

arrow
arrow

N/A

-45.58
vs -40.93

Q3.23

arrow
arrow

N/A

-19.49
vs -21.89

Q4.23

arrow
arrow

N/A

-21.89
vs -6.76

Q1.24

arrow
arrow

N/A

-9.15
vs -11.24

Q2.24

arrow
arrow

N/A

-3.75
vs -45.58

Q3.24

arrow
arrow

N/A

-3.60
vs -19.49

Q4.24

arrow
arrow

N/A

-3.45
vs -21.89

Q1.25

arrow
arrow

N/A

-6.00
vs -9.15

Sales GrowthShape

status-upYoY

Current

Estimates

Q2.22

arrow
arrow

NA

NA  vs NA

Q3.22

arrow
arrow

NA

NA  vs NA

Q4.22

arrow
arrow

NA

NA  vs NA

Q1.23

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q3.23

arrow
arrow

NA

NA  vs NA

Q4.23

arrow
arrow

NA

647.1K  vs NA

Q1.24

arrow
arrow

NA

NA  vs NA

Q2.24

arrow
arrow

NA

NA  vs NA

Q3.24

arrow
arrow

NA

NA  vs NA

Return on EquityShape

status-upQoQ

Q4.22

arrow
arrow

-96%

-0.96
vs 0.03

Q1.23

arrow
arrow

-44%

-0.44
vs -0.96

Q2.23

arrow
arrow

-131%

-1.31
vs -0.44

Q3.23

arrow
arrow

-116%

-1.16
vs -1.31

Q4.23

arrow
arrow

-91%

-0.91
vs -1.16

Q1.24

arrow
arrow

-38%

-0.38
vs -0.91

Q2.24

arrow
arrow

-35%

-0.35
vs -0.38

Q3.24

arrow
arrow

-53%

-0.53
vs -0.35

Institutionnal OwnershipShape

status-upQoQ

Q1.23

arrow
arrow

12

12
vs 10

20%

Q2.23

arrow
arrow

14

14
vs 12

17%

Q3.23

arrow
arrow

14

14
vs 14

NA

Q4.23

arrow
arrow

14

14
vs 14

NA

Q1.24

arrow
arrow

17

17
vs 14

21%

Q2.24

arrow
arrow

17

17
vs 17

NA

Q3.24

arrow
arrow

16

16
vs 17

-6%

Q4.24

arrow
arrow

19

19
vs 16

19%

Earnings Growth

Latest News

ENVB

businesswire.com

9 hours ago

Enveric Biosciences CEO Issues Letter to Shareholders
ENVB

businesswire.com

10 hours ago

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark
ENVB

businesswire.com

13 hours ago

Enveric Biosciences Participating in BIO-Europe Spring®
ENVB

businesswire.com

13 hours ago

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent
ENVB

businesswire.com

17 hours ago

Enveric Biosciences Announces Closing of $5 Million Public Offering
ENVB

businesswire.com

20 hours ago

Enveric Biosciences Announces Pricing of $5 Million Public Offering